The first trials to use ICI in sarcomas either as monotherapy with programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors [4, 5], or in combination with CTLA-4 inhibitors [4, 6], demonstrated limited efficacy in unselected sarcoma population with some isolated radiological responses. The gene discussed is CTLA4; the disease is sarcoma.